IMPL Insider Trading
Notice: This stock is marked as potentially delisted. It may not be actively trading.
Insider Ownership Percentage: 6.20%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $0.00
Impel Pharmaceuticals Share Price & Price History
Current Price: $0.00
Price Change: +0.30 (1.20%)
As of 12/21/2023 12:59 AM ET
Impel Pharmaceuticals Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 12/18/2023 | Vivo Capital Viii, Llc | Major Shareholder | Sell | 237,711 | $0.11 | $26,148.21 | 308,926 |  |
| 12/15/2023 | Vivo Capital Viii, Llc | Major Shareholder | Sell | 100,000 | $0.29 | $29,000.00 | 337,608 | |
Impel Pharmaceuticals Institutional Trading History
| Reporting Date | Hedge Fund | Shares Held | Market Value | % of Portfolio | Quarterly Change in Shares | Ownership in Company | Details |
|---|
| 11/15/2023 | Lasry Marc | 225,874 | $97K | 0.1% | -44.7% | 0.951% |  |
| 8/9/2023 | DCF Advisers LLC | 303,605 | $0.39M | 0.2% | -20.8% | 1.278% | |
| 7/17/2023 | Mcdonald Partners LLC | 20,200 | $26K | 0.0% | +72.6% | 0.085% | |
| 1/18/2023 | Mcdonald Partners LLC | 11,700 | $44K | 0.0% | N/A | 0.049% | |
| 11/14/2022 | Ergoteles LLC | 24,447 | $0.12M | 0.0% | -13.9% | 0.103% | |
| 8/15/2022 | Opaleye Management Inc. | 144,642 | $1.35M | 0.6% | N/A | 0.624% | |
| 8/15/2022 | Laurion Capital Management LP | 124,800 | $1.16M | 0.0% | N/A | 0.539% | |
| 8/11/2022 | DCF Advisers LLC | 438,566 | $4.09M | 2.4% | +19.5% | 1.893% | |
| 5/9/2022 | Qube Research & Technologies Ltd | 11,867 | $76K | 0.0% | -41.7% | 0.051% | |
| 2/14/2022 | Point72 Hong Kong Ltd | 5,864 | $51K | 0.0% | N/A | 0.025% | |
| 2/14/2022 | Point72 Asset Management L.P. | 208,760 | $1.80M | 0.0% | N/A | 0.906% | |
| 2/10/2022 | Qube Research & Technologies Ltd | 20,342 | $0.18M | 0.0% | N/A | 0.088% | |
| 2/9/2022 | Alps Advisors Inc. | 26,662 | $0.23M | 0.0% | N/A | 0.116% | |
| 2/3/2022 | Brighton Jones LLC | 14,145 | $0.12M | 0.0% | N/A | 0.061% | |
| 2/1/2022 | Qube Research & Technologies Ltd | 20,342 | $0.18M | 0.0% | N/A | 0.088% | |
| 1/28/2022 | Allspring Global Investments Holdings LLC | 26,675 | $0.23M | 0.0% | N/A | 0.116% | |
| 1/25/2022 | Epiq Partners LLC | 18,646 | $0.16M | 0.1% | N/A | 0.081% | |
| 12/10/2021 | Towercrest Capital Management | 50,500 | $0.62M | 0.1% | N/A | 0.219% | |
| 11/15/2021 | First Manhattan Co. | 6,700 | $81K | 0.0% | N/A | 0.034% | |
| 11/12/2021 | Geode Capital Management LLC | 117,916 | $1.44M | 0.0% | +131.5% | 0.604% | |
| 11/9/2021 | BlackRock Inc. | 268,730 | $3.27M | 0.0% | +7.0% | 1.377% | |
| 11/8/2021 | Trustcore Financial Services LLC | 13,407 | $0.16M | 0.0% | N/A | 0.069% | |
| 11/8/2021 | Russell Investments Group Ltd. | 200,806 | $2.45M | 0.0% | N/A | 1.029% | |
| 11/2/2021 | New York State Common Retirement Fund | 6,867 | $84K | 0.0% | -49.9% | 0.035% | |
| 11/2/2021 | Victory Capital Management Inc. | 80,390 | $0.98M | 0.0% | -28.7% | 0.412% | |
| 8/16/2021 | State Street Corp | 46,298 | $0.41M | 0.0% | N/A | 0.208% | |
Data available starting January 2016
Impel Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for patients suffering from central nervous system disease in the United States. Its lead product candidate is Trudhesa, an upper nasal formulation of dihydroergotamine for the acute treatment of migraine. Impel Pharmaceuticals Inc. was formerly known as Impel NeuroPharma, Inc. and changed its name to Impel Pharmaceuticals Inc. in April 2022. The company was incorporated in 2008 and is headquartered in Seattle, Washington.
Read More on Impel Pharmaceuticals
Today's Range
Now: N/A
52 Week Range
Now: N/A
Volume
720,000 shs
Average Volume
682,655 shs
Market Capitalization
$956 thousand
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.17
Who are the company insiders with the largest holdings of Impel Pharmaceuticals?
